Drug Trial Radar · NCT00487539
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Feb 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,065
Actual
Start
Aug 2007
Primary completion
Oct 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).
Conditions
- Colitis, Ulcerative
Interventions
PlaceboBiological
Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
Golimumab 100 mgBiological
Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.
Golimumab 200 mgBiological
Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.
Golimumab 400 mgBiological
Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -\> 200 mg arm group.
Golimumab 50 mgBiological
Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -\> 50 mg arm group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinical Response at Week 6Time frame: Baseline, Week 6
Locations
200 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Little Rock, Arkansas
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
Golden, Colorado
Site not named
Newark, Delaware
Site not named
Boca Raton, Florida
Site not named
Gainesville, Florida
Site not named
Hialeah, Florida
Site not named
Naples, Florida
Site not named
New Port Richey, Florida
Site not named
Port Orange, Florida
Site not named
Winter Park, Florida
Site not named
Zephyrhills, Florida
Site not named
Atlanta, Georgia
Site not named
Savannah, Georgia
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Clive, Iowa
Site not named
Pratt, Kansas
Site not named
Lexington, Kentucky
Site not named
Monroe, Louisiana
Site not named
Ann Arbor, Michigan
Site not named
Troy, Michigan
Site not named
Rochester, Minnesota
Site not named
Pascagoula, Mississippi
Site not named
Tupelo, Mississippi
Site not named
Egg Harbor, New Jersey
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Asheville, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Morganton, North Carolina
Site not named
New Bern, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Wilmington, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Fargo, North Dakota
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Showing 40 of 200 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.